Description

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].-4°C (Powder, sealed storage, away from moisture and light)-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19.|[2]Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65.-CASNumber-914088-09-8-MolecularWeight-153000 (average) -Compound Purity-98.00-SMILES-[Brentuximab vedotin]-Research_Area-Cancer-Solubility-H2O-Target-Antibody-Drug Conjugates (ADCs);Apoptosis;TNF Receptor-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Apoptosis-MCE Product type-ADC Related